Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Fall, Bécaye ; Madamet, Marylin ; Camara, Cheikhou ; Amalvict, Rémy ; Fall, Mansour ; Nakoulima, Aminata ; Diatta, Bakary ; Diémé, Yaya ; Wade, Boubacar ; Pradines, Bruno
• Description:
  We successfully cultured 36 Plasmodium falciparum isolates from blood samples of 44 malaria patients admitted to the Hôpital Principal de Dakar (Dakar, Senegal) during August-December 2014. The prevalence of isolates with in vitro reduced susceptibility was 30.6% for monodesethylamodiaquine, 52.8% for chloroquine, 44.1% for mefloquine, 16.7% for doxycycline, 11.8% for piperaquine, 8.3% for artesunate, 5.9% for pyronaridine, 2.8% for quinine and dihydroartemisinin, and 0.0% for lumefantrine. The prevalence of isolates with reduced in vitro susceptibility to the artemisinin-based combination therapy partner monodesethylamodiaquine increased from 5.6% in 2013 to 30.6% in 2014. Because of the increased prevalence of P. falciparum parasites with impaired in vitro susceptibility to monodesethylamodiaquine, the implementation of in vitro and in vivo surveillance of all artemisinin-based combination therapy partners is warranted.
• Subjects:
  Amodiaquine Antimalarials Drug Resistance Female Humans Inhibitory Concentration 50 Malaria, Falciparum Male Parasitic Sensitivity Tests Plasmodium Falciparum/drug Effects Prevalence Research

  More +
• Source:
  Emerg Infect Dis. 22(5):841-845.
• Pubmed ID:
  27088703
• Pubmed Central ID:
  PMC4861513
• Document Type:
  Journal Article
• Place as Subject:
  Senegal
• Location:
  Africa
• Volume:
  22
• Issue:
  5
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:5c5805c77deb7bf7894e09f8b3e093fa2814ec360ab07694288c3920149fd593
• Download URL:
  https://stacks.cdc.gov/view/cdc/39361/cdc_39361_DS1.pdf
• File Type:
  [PDF - 341.55 KB ]